Evidence map›Paper›PMID 27941937›Full record

Trial reportScientific reports2016

NKp30

Xiaokun Shen, Binqing Fu, Yanyan Liu, Chuang Guo, Ying Ye, Rui Sun, Jiabin Li, Zhigang Tian, Haiming Wei

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. NKp30: A Key Membrane Molecule in the Fight Against Cancer and Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Neutrophils inhibit CD8World journal of emergency medicine · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xiaokun ShenInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
Binqing FuInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
Yanyan LiuDepartment of Infectious Diseases, First Affiliated Hospital of Anhui Medical University and Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China.
Chuang GuoInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
Ying YeDepartment of Infectious Diseases, First Affiliated Hospital of Anhui Medical University and Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China.
Rui SunInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
Jiabin LiDepartment of Infectious Diseases, First Affiliated Hospital of Anhui Medical University and Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhigang TianInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
Haiming WeiInstitute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui 230027, China.
University of Science and Technology of China · CNFirst Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CNHefei National Center for Physical Sciences at Nanoscale · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pressing need exists for improved therapeutic options for chronic hepatitis B (CHB). Pegylated-interferon-alpha (Peg-IFN-α) achieves sustained off-treatment responses in many cases because of its direct anti-viral effects and regulation of the immune response. However, non-responsiveness to Peg-IFN-α is frequent, and the mechanism is poorly understood. In this study, we found that the frequency and absolute number of NKp30

Indexed as

Hepatitis B, ChronicNatural Cytotoxicity Triggering Receptor 3AdultFemaleHumansImmunity, CellularInterferon-alphaInterferon alpha-2Interferon-gammaKiller Cells, NaturalLysosomal-Associated Membrane Protein 1MaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsIFNG protein, humanInterferon-alphaInterferon alpha-2Interferon-gammaLysosomal-Associated Membrane Protein 1Natural Cytotoxicity Triggering Receptor 3NCR3 protein, humanpeginterferon alfa-2bPolyethylene GlycolsRecombinant Proteins

Identifiers

PMID27941937
PMCPMC5150634
OpenAlexW2567081150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.